These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
87 related articles for article (PubMed ID: 22798231)
1. Spiral analysis in subjects with Parkinson's disease before and after levodopa treatment: a new protocol with stereophotogrammetric systems. Galli M; Vimercati SL; Manetti E; Cimolin V; Albertini G; De Pandis MF J Appl Biomater Funct Mater; 2014 Sep; 12(2):e107-12. PubMed ID: 22798231 [TBL] [Abstract][Full Text] [Related]
2. Dopaminergic treatment is associated with decreased body weight in patients with Parkinson's disease and dyskinesias. Bachmann CG; Zapf A; Brunner E; Trenkwalder C Eur J Neurol; 2009 Aug; 16(8):895-901. PubMed ID: 19374662 [TBL] [Abstract][Full Text] [Related]
3. Prosody and levodopa in Parkinson's disease. Azevedo LL; Reis CA; Souza IS; Cardoso FE Arq Neuropsiquiatr; 2013 Nov; 71(11):835-40. PubMed ID: 24394867 [TBL] [Abstract][Full Text] [Related]
4. Levodopa influences striatal activity but does not affect cortical hyper-activity in Parkinson's disease. Martinu K; Degroot C; Madjar C; Strafella AP; Monchi O Eur J Neurosci; 2012 Feb; 35(4):572-83. PubMed ID: 22304628 [TBL] [Abstract][Full Text] [Related]
5. Hand coordination as a quantitative measure of motor abnormality and therapeutic response in Parkinson's disease. Benice TS; Lou JS; Eaton R; Nutt J Clin Neurophysiol; 2007 Aug; 118(8):1776-84. PubMed ID: 17576094 [TBL] [Abstract][Full Text] [Related]
6. Levodopa/carbidopa microtablets in Parkinson's disease: a study of pharmacokinetics and blinded motor assessment. Senek M; Aquilonius SM; Askmark H; Bergquist F; Constantinescu R; Ericsson A; Lycke S; Medvedev A; Memedi M; Ohlsson F; Spira J; Westin J; Nyholm D Eur J Clin Pharmacol; 2017 May; 73(5):563-571. PubMed ID: 28101657 [TBL] [Abstract][Full Text] [Related]
7. Levodopa improves time-based prospective memory in Parkinson's disease. Costa A; Peppe A; Brusa L; Caltagirone C; Gatto I; Carlesimo GA J Int Neuropsychol Soc; 2008 Jul; 14(4):601-10. PubMed ID: 18577289 [TBL] [Abstract][Full Text] [Related]
8. Profile of levodopa-induced dyskinesia in patients of Parkinson's disease: a record based study. Choudhury S; Pradhan R; Paul P; Das M; Gupta A; Ghosh P; Chatterjee S Neurol Res; 2014 Sep; 36(9):841-6. PubMed ID: 24601722 [TBL] [Abstract][Full Text] [Related]
9. Slowing of oscillatory brain activity is a stable characteristic of Parkinson's disease without dementia. Stoffers D; Bosboom JL; Deijen JB; Wolters EC; Berendse HW; Stam CJ Brain; 2007 Jul; 130(Pt 7):1847-60. PubMed ID: 17412733 [TBL] [Abstract][Full Text] [Related]
10. Interaction of levodopa and cues on voluntary reaching in Parkinson's disease. Kelly VE; Hyngstrom AS; Rundle MM; Bastian AJ Mov Disord; 2002 Jan; 17(1):38-44. PubMed ID: 11835437 [TBL] [Abstract][Full Text] [Related]
11. Locomotor response to levodopa in fluctuating Parkinson's disease. Moore ST; MacDougall HG; Gracies JM; Ondo WG Exp Brain Res; 2008 Feb; 184(4):469-78. PubMed ID: 17828529 [TBL] [Abstract][Full Text] [Related]
12. Intrajejunal levodopa infusion in advanced Parkinson's disease: long-term effects on motor and non-motor symptoms and impact on patient's and caregiver's quality of life. Fasano A; Ricciardi L; Lena F; Bentivoglio AR; Modugno N Eur Rev Med Pharmacol Sci; 2012 Jan; 16(1):79-89. PubMed ID: 22338551 [TBL] [Abstract][Full Text] [Related]
14. Comparative analysis of gait and speech in Parkinson's disease: hypokinetic or dysrhythmic disorders? Cantiniaux S; Vaugoyeau M; Robert D; Horrelou-Pitek C; Mancini J; Witjas T; Azulay JP J Neurol Neurosurg Psychiatry; 2010 Feb; 81(2):177-84. PubMed ID: 19793764 [TBL] [Abstract][Full Text] [Related]
15. Subthalamic Nucleus Deep Brain Stimulation Modulate Catecholamine Levels with Significant Relations to Clinical Outcome after Surgery in Patients with Parkinson's Disease. Yamamoto T; Uchiyama T; Higuchi Y; Asahina M; Hirano S; Yamanaka Y; Kuwabara S PLoS One; 2015; 10(9):e0138462. PubMed ID: 26394059 [TBL] [Abstract][Full Text] [Related]
16. Three-dimensional gait biomechanics in Parkinson's disease: evidence for a centrally mediated amplitude regulation disorder. Morris M; Iansek R; McGinley J; Matyas T; Huxham F Mov Disord; 2005 Jan; 20(1):40-50. PubMed ID: 15390033 [TBL] [Abstract][Full Text] [Related]
17. Asymmetrical effect of levodopa on the neural activity of motor regions in PD. Martinu K; Nagano-Saito A; Fogel S; Monchi O PLoS One; 2014; 9(11):e111600. PubMed ID: 25369523 [TBL] [Abstract][Full Text] [Related]
18. Does levodopa slow or hasten the rate of progression of Parkinson's disease? Fahn S; J Neurol; 2005 Oct; 252 Suppl 4():IV37-IV42. PubMed ID: 16222436 [TBL] [Abstract][Full Text] [Related]
19. A new computer method for assessing drawing impairment in Parkinson's disease. Westin J; Ghiamati S; Memedi M; Nyholm D; Johansson A; Dougherty M; Groth T J Neurosci Methods; 2010 Jun; 190(1):143-8. PubMed ID: 20438759 [TBL] [Abstract][Full Text] [Related]
20. Predictive timing functions of cortical beta oscillations are impaired in Parkinson's disease and influenced by L-DOPA and deep brain stimulation of the subthalamic nucleus. Gulberti A; Moll CK; Hamel W; Buhmann C; Koeppen JA; Boelmans K; Zittel S; Gerloff C; Westphal M; Schneider TR; Engel AK Neuroimage Clin; 2015; 9():436-49. PubMed ID: 26594626 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]